PALI Stock Price, Palisade Bio, Inc. Quote, Chart

Market Summary

USD6.09-0.14

Market Closed

-2.25%

PALI Stock Price

View Fullscreen

PALI RSI Chart

PALI Valuation

Market Cap

5.2M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

20.74

Price/Free Cashflow

-0.47

PALI Price/Sales (Trailing)

PALI Profitability

Return on Equity

-108.72%

Return on Assets

-87.53%

Free Cashflow Yield

-214.79%

PALI Fundamentals

PALI Revenue

Revenue (TTM)

250.0K

Rev. Growth (Yr)

-100%

PALI Earnings

Earnings (TTM)

-12.3M

Earnings Growth (Yr)

20.13%

Earnings Growth (Qtr)

17.38%

Breaking Down PALI Revenue

Last 7 days

29.3%

Last 30 days

1.5%

Last 90 days

-21.9%

Trailing 12 Months

-77.7%

How does PALI drawdown profile look like?

PALI Financial Health

Current Ratio

5.15

PALI Investor Care

Shares Dilution (1Y)

179.82%

Diluted EPS (TTM)

-27.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	108.1K	155.4K	202.7K	250.0K
2022	0	0	0	60.8K
2020	18.9K	13.5K	13.5K	13.5K
2019	198.8K	137.7K	76.5K	15.4K
2018	260.0K	260.0K	260.0K	260.0K
2017	16.2K	16.2K	16.2K	260.0K
2016	10.0K	10.0K	10.0K	16.2K
2015	17.6K	15.1K	12.6K	10.4K
2014	11.7K	14.2K	16.7K	18.8K
2013	354.0K	278.3K	110.0K	110.0K
2012	394.9K	399.2K	403.4K	407.7K
2011	0	0	562.0K	390.6K
2010	0	0	0	733.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Palisade Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	finley john david	acquired	-	-	5,558	ceo, cfo, director
Feb 09, 2024	neal james r	acquired	-	-	10,920	-
Feb 08, 2024	trenschel robert j.	acquired	-	-	10,920	-
Feb 08, 2024	csimma cristina	acquired	-	-	12,800	-
Feb 08, 2024	diaz stephanie	acquired	-	-	12,800	-
Feb 06, 2024	jones mitchell lawrence	sold (taxes)	-938	0.4361	-2,153	chief medical officer
Feb 06, 2024	jones mitchell lawrence	acquired	-	-	6,891	chief medical officer
Feb 06, 2024	finley john david	acquired	-	-	6,642	ceo, cfo, director
Feb 06, 2024	finley john david	bought	4,692	0.4692	10,000	ceo, cfo, director
Jan 31, 2024	finley john david	bought	5,590	0.559	10,000	ceo, cfo, director

Which funds bought or sold PALI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BFSG, LLC	new	-	16.00	16.00	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	545	40,152	-%
Feb 26, 2024	Virtu Financial LLC	new	-	31,000	31,000	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	180	13,253	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	11,595	11,595	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	276	20,324	-%
Feb 13, 2024	MORGAN STANLEY	added	3.33	57.00	1,244	-%
Feb 13, 2024	FMR LLC	new	-	22.00	22.00	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-	5.00	-%
Feb 13, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-	1.00	-%

Are Funds Buying or Selling PALI?

Are funds buying PALI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PALI

No. of Funds

Unveiling Palisade Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	486,914	SC 13G/A
Feb 13, 2024	lind global fund ii lp	1.7%	158,355	SC 13G/A
Feb 09, 2024	l1 capital global opportunities master fund, ltd.	0%	0	SC 13G/A
Feb 06, 2024	intracoastal capital, llc	1.9%	180,532	SC 13G/A
Sep 15, 2023	lind global fund ii lp	7.9%	743,313	SC 13G
Sep 15, 2023	l1 capital global opportunities master fund, ltd.	6.4%	584,958	SC 13G
Feb 14, 2023	altium capital management lp	0%	0	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	281,054	SC 13G
Feb 13, 2023	lind global fund ii lp	1.4%	30,987	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	5.7%	131,086	SC 13G/A

Recent SEC filings of Palisade Bio, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	8-K	Current Report
Apr 05, 2024	EFFECT	EFFECT
Apr 05, 2024	424B3	Prospectus Filed
Apr 05, 2024	8-K	Current Report
Mar 29, 2024	S-3	S-3
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 27, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	8-K	Current Report

Peers (Alternatives to Palisade Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Palisade Bio, Inc. News

Latest updates

Palisade Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-	-	-	-	250	126	3.00	3.00	3.00	6.00	3.00	3.00	8.00	5.00	3.00	3.00	253	253	253	3.00	3.00	3.00
Operating Expenses	-16.5%	3,154	3,778	3,609	2,779	3,848	3,444	1,816	1,841	1,996	2,135	2,127	1,926	2,459	1,807	2,085	2,275	2,351	-	-	-	-
S&GA Expenses	-6.9%	1,558	1,674	1,432	1,538	1,505	2,382	1,404	1,191	1,300	1,368	1,301	972	945	928	1,188	1,261	1,182	-	-	-	-
R&D Expenses	-	-	-	-	-	-	410	466	446	697	767	825	954	1,514	879	897	1,015	1,169	1,225	1,384	2,585	2,902
Interest Expenses	-50.0%	4.00	8.00	3.00	-	3.00	-	28.00	11.00	3.00	4.00	2.00	507*	2.00	4.00	1.00	772*	-	-	-	-	-
Net Income	17.4%	-2,971	-3,596	-3,393	-2,340	-3,720	-4,244	-1,843	-1,851	-2,384	-2,037	-1,763	-1,436	-3,113	-320	-1,830	-627	-2,146	-	-	-	-
Net Income Margin	23.6%	-49.20*	-64.37*	-86.51*	-114.65*	-234.48*	-763.46*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-3.2%	-2,746	-2,662	-2,209	-3,536	-3,316	-1,549	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-17.7%	14,052	17,067	18,290	15,262	15,763	16,266	7,806	8,350	12,512	16,274	14,949	8,915	3,019	15,170	17,102	11,361	6,584	8,944	3,522	5,406	7,684
Current Assets	-18.1%	13,328	16,266	17,411	14,309	14,733	15,158	7,415	8,258	11,506	16,092	14,725	8,756	896	14,991	16,242	10,464	5,647	7,966	2,708	4,538	6,508
Cash Equivalents	-18.8%	12,432	15,312	16,403	13,297	12,383	13,985	4,980	6,644	10,495	14,104	12,653	615	713	751	1,519	10,030	5,115	7,300	2,281	4,005	5,787
Net PPE	0%	10.00	10.00	11.00	9.00	10.00	12.00	2.00	2.00	3.00	3.00	3.00	7.00	5.00	15.00	22.00	31.00	41.00	52.00	63.00	76.00	90.00
Liabilities	-8.2%	2,739	2,985	2,490	1,515	3,284	3,836	3,595	3,558	5,147	12,354	24,393	1,186	10,118	1,047	867	1,383	1,458	1,901	1,559	2,134	1,635
Current Liabilities	-2.4%	2,586	2,649	2,335	1,315	3,012	3,513	2,860	1,864	2,496	2,920	3,850	1,015	8,082	1,002	676	1,186	1,225	1,581	1,071	1,210	1,051
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	94.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	94.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-19.7%	11,313	14,082	15,800	13,747	12,479	12,430	4,211	4,792	7,365	3,920	-	7,729	9,768	14,122	16,234	9,978	5,126	7,043	1,963	3,272	6,050
Retained Earnings	-	121,500	-	-	-	-	-	-	-	-	-95,715	-103,800	-240,527	-68,026	-233,823	-231,501	-229,550	-221,975	-219,937	-218,174	-216,737	-213,623
Additional Paid-In Capital	0.2%	132,724	132,523	130,652	125,229	121,637	116,839	105,180	103,454	102,002	99,503	94,242	248,228	51,396	247,775	247,568	239,440	227,067	226,958	220,125	219,993	219,655
Shares Outstanding	0.7%	618	614	457	304	196	38.00	24.00	22.00	19.00	11.00	15.00	4.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	11,600	-	-	-	8,100	-	-	-	39,200	-	-	-	12,444	-	-	-	4,578	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-3.2%	-2,746	-2,662	-2,199	-3,526	-3,306	-3,040	-3,250	-3,764	-3,055	-2,746	-7,722	-1,250	-1,548	-869	-673	-1,677	-2,048	-1,897	-1,643	-1,665	-1,658
Share Based Compensation	-8.4%	185	202	144	93.00	86.00	252	336	358	683	144	495	569	470	664	804	76.00	119	295	129	338	64.00
Cashflow From Investing	-	-	-	-	-	-10.00	-	-	-	-	-348	-	-	-1.00	1.00	-	-	-	-	-	-	-1.71
Cashflow From Financing	-108.5%	-134	1,571	5,309	4,440	1,714	12,045	1,586	-87.00	-554	4,545	19,466	1,152	1,511	100	-6,314	6,593	-136	6,922	-78.85	-117	1,712

PALI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
License revenue	$ 250	$ 0
Research and development	6,893	6,547
General and administrative	6,202	8,764
Restructuring costs (Note 9)	225	410
Total operating expenses	13,320	15,721
Loss from operations	(13,070)	(15,721)
Other income (expense):
Interest expense	(15)	(13)
Other income	785	2,584
Loss on issuance of warrants	0	(1,110)
Total other income, net	770	1,461
Net loss	(12,300)	(14,260)
Net loss available to common stockholders	$ (12,316)	$ (14,548)
Loss per common share:
Basic net loss per common share	$ (1.8)	$ (16.53)
Diluted net loss per common share	$ (1.8)	$ (16.53)
Weighted average shares used in computing loss per common share:
Basic weighted average shares used in computing net loss per common share	6,840,213	880,311
Diluted weighted average shares used in computing net loss per common share	6,840,213	880,311

PALI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 12,432,000	$ 12,383,000
Prepaid expenses and other current assets	896,000	2,350,000
Total current assets	13,328,000	14,733,000
Restricted cash	26,000	26,000
Property and equipment, net	10,000	10,000
Operating lease right-of-use asset	198,000	300,000
Other noncurrent assets	490,000	694,000
Total assets	14,052,000	15,763,000
Current liabilities:
Accounts payable	698,000	1,759,000
Accrued liabilities	831,000	574,000
Accrued compensation and benefits	778,000	486,000
Current portion of operating lease liability	121,000	105,000
Insurance financing debt	158,000	88,000
Total current liabilities	2,586,000	3,012,000
Warrant liability	2,000	61,000
Contingent consideration obligation	61,000	0
Lease liability, net of current portion	90,000	211,000
Total liabilities	2,739,000	3,284,000
Commitments and contingencies (Note 9)
Stockholders' equity:
Common stock, $0.01 par value; 280,000,000 shares authorized; 9,270,894 and 2,944,306 shares issued and outstanding at December 31,2023 and December 31, 2022, respectively	93,000	30,000
Additional paid-in capital	132,724,000	121,637,000
Accumulated deficit	(121,506,000)	(109,190,000)
Total stockholders' equity	11,313,000	12,479,000
Total liabilities and stockholders' equity	14,052,000	15,763,000
Series A Preferred Stock [Member]
Stockholders' equity:
Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at December 31, 2023 and December 31, 2022	$ 2,000	$ 2,000

About Palisade Bio, Inc.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

CEO	Mr. J. D. Finley
WEBSITE	palisadebio.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Palisade Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Palisade Bio, Inc.? What does PALI stand for in stocks?

PALI is the stock ticker symbol of Palisade Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Palisade Bio, Inc. (PALI)?

As of Fri Apr 26 2024, market cap of Palisade Bio, Inc. is 5.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PALI stock?

You can check PALI's fair value in chart for subscribers.

What is the fair value of PALI stock?

You can check PALI's fair value in chart for subscribers. The fair value of Palisade Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Palisade Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PALI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Palisade Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether PALI is over valued or under valued. Whether Palisade Bio, Inc. is cheap or expensive depends on the assumptions which impact Palisade Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PALI.

What is Palisade Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, PALI's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 20.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PALI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Palisade Bio, Inc.'s stock?

In the past 10 years, Palisade Bio, Inc. has provided -0.74 (multiply by 100 for percentage) rate of return.